Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma
Primary liver cancer (PLC) is the first leading cause of immature cancer death in China. Hepatocellular carcinoma (HCC) in China accounts for 93.0% of PLC. Chronic infection with hepatitis B virus (HBV) HCC contributes to 84.4% of HCC. During HBV-induced hepatocarcinogenesis, non-resolving inflammat...
Main Author: | CAO Guangwen |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-08-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0377 |
Similar Items
-
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
by: Carmelo Laface, et al.
Published: (2023-01-01) -
Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma
by: Li Z, et al.
Published: (2023-11-01) -
PTEN-related risk classification models for predicting prognosis and immunotherapy response of hepatocellular carcinoma
by: Lu Cao, et al.
Published: (2023-07-01) -
Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects
by: Ya-ruo Lei, et al.
Published: (2024-02-01) -
Hepatocellular Carcinoma—The Influence of Immunoanatomy and the Role of Immunotherapy
by: Keyur Patel, et al.
Published: (2020-09-01)